|
1
|
Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou
XN, Chen R, Gu XY, Wei WW and He J: Report of cancer epidemiology
in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:19–28. 2019.(In
Chinese; Abstract available in Chinese from the publisher).
PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of randomized trials. Lancet. 365:1687–1717.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silberholz J, Bertsimas D and Vahdat L:
Clinical benefit, toxicity and cost of metastatic breast cancer
therapies: Systematic review and meta-analysis. Breast Cancer Res
Treat. 176:535–543. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alarid-Escudero F, Blaes AH and Kuntz KM:
Trade-offs between efficacy and cardiac toxicity of adjuvant
chemotherapy in early-stage breast cancer patients: Do competing
risks matter? Breast J. 23:401–409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Abreu FB, Schwartz GN, Wells WA and
Tsongalis GJ: Personalized therapy for breast cancer. Clin Genet.
86:62–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel
Members, : Tailoring therapies-Improving the management of early
breast cancer: St gallen international expert consensus on the
primary therapy of early breast cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members, : Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the st gallen international expert consensus on the primary therapy
of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA
Jr, et al: Prospective validation of a 21-gene expression assay in
breast cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gluz O, Nitz UA, Christgen M, Kates RE,
Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, et al:
West German Study Group Phase III PlanB trial: First prospective
outcome data for the 21-gene recurrence score assay and concordance
of prognostic markers by central and local pathology assessment. J
Clin Oncol. 34:2341–2349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paik S, Tang G, Shak S, Kim C, Baker J,
Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albain KS, Barlow WE, Shak S, Hortobagyi
GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, et al: Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: A
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA
Jr, et al: Adjuvant chemotherapy guided by a 21-gene expression
assay in breast cancer. N Engl J Med. 379:111–121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Network NCC, . NCCN Clinical Practice
Guidlines in Oncology. Breast Cancer. Version 2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdfApril
6–2017
|
|
15
|
Hornberger J, Alvarado MD, Rebecca C,
Gutierrez HR, Yu TM and Gradishar WJ: Clinical validity/utility,
change in practice patterns, and economic implications of risk
stratifiers to predict outcomes for early-stage breast cancer: A
systematic review. J Natl Cancer Inst. 104:1068–1079. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Habel LA, Shak S, Jacobs MK, Capra A,
Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, et al:
A population-based study of tumor gene expression and risk of
breast cancer death among lymph node-negative patients. Breast
Cancer Res. 8:R252006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dowsett M, Cuzick J, Wale C, Forbes J,
Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, et al:
Prediction of risk of distant recurrence using the 21-gene
recurrence score in node-negative and node-positive postmenopausal
patients with breast cancer treated with anastrozole or tamoxifen:
A TransATAC study. J Clin Oncol. 28:1829–1834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno
S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S and Kuroi K;
Japan Breast Cancer Research Group-Translational Research Group, :
Clinical significance of the 21-gene signature (Oncotype DX) in
hormone receptor-positive early stage primary breast cancer in the
Japanese population. Cancer. 116:3112–3118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van der Hoeven JJ: 70-Gene signature as an
aid to treatment decisions in early-stage breast cancer. Ned
Tijdschr Geneeskd. 161:D13692017.(In Dutch). PubMed/NCBI
|
|
20
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the st gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO classification of tumours of the
breastWorld Health Organization Classification of Tumours. 4th.
International Agency for Research on Cancer; Lyon: pp. 60–61.
2012
|
|
23
|
Edge S, Byrd D and Compton C: AJCC Cancer
Staging Handbook7th. American Joint Committee on Cancer. Springer;
New York, NY: 2010, PubMed/NCBI
|
|
24
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu J, Fang Y, Lin L, Fei X, Gao W, Zhu S,
Zong Y, Chen X, Huang O, He J, et al: Distribution patterns of
21-gene recurrence score in 980 Chinese estrogen receptor-positive,
HER2-negative early breast cancer patients. Oncotarget.
8:38706–38716. 2017.PubMed/NCBI
|
|
26
|
Cronin M, Sangli C, Liu ML, Pho M, Dutta
D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical
validation of the Oncotype DX genomic diagnostic test for
recurrence prognosis and therapeutic response prediction in
node-negative, estrogen receptor-positive breast cancer. Clin Chem.
53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Esteban J, Baker J, Cronin M, et al: Tumor
gene expression and prognosis in breast cancer: Multi-gene RT-PCR
assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol.
22:8502003.
|
|
28
|
Paik S, Shak S, Tang G, et al: Multi-gene
RT-PCR assay for predicting recurrence in node negative breast
cancer patients: NSABP studies B-20 and B-14. Breast Cancer Res
Treat. 82:A162003.
|
|
29
|
Cobleigh MA, Bitterman P, Baker J, et al:
Tumor gene expression predicts distant disease-free survival (DDFS)
in breast cancer patients with 10 or more positive nodes: High
throughout RT-PCR assay of paraffin-embedded tumor tissues. Prog
Proc Am Soc Clin Oncol. 22:8502003.
|
|
30
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harris LN, Ismaila N, McShane LM, Andre F,
Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC,
Mennel RG, et al: Use of biomarkers to guide decisions on adjuvant
systemic therapy for women with early-stage invasive breast cancer:
American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 34:1134–1150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arima N, Nishimura R, Osako T, Okumura Y,
Nakano M, Fujisue M, Nishiyama Y and Toyozumi Y: Ki-67 index value
and progesterone receptor status can predict prognosis and suitable
treatment in node-negative breast cancer patients with estrogen
receptor-positive and HER2-negative tumors. Oncol Lett. 17:616–622.
2019.PubMed/NCBI
|
|
33
|
Zhu L, Ma N, Wang B, Zhou C, Yan Y, Wang
K, He J and Ren Y: Clinical analysis of 21-gene recurrence score
test in hormone receptor-positive early-stage breast cancer. Oncol
Lett. 17:5469–5480. 2019.PubMed/NCBI
|
|
34
|
Nitz U, Gluz O, Christgen M, Kates RE,
Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, et al:
Reducing chemotherapy use in clinically high-risk, genomically
low-risk pN0 and pN1 early breast cancer patients: Five-year data
from the prospective, randomised phase 3 West German Study Group
(WSG) PlanB trial. Breast Cancer Res Treat. 165:573–583. 2017.
View Article : Google Scholar : PubMed/NCBI
|
